Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1B1 | P15121 | 15/20 | 0.82 |
| ▸ | AKR1A1 | P14550 | 14/20 | 0.82 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.58 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | HTR2A | P28223 | 1/20 | 0.43 |
| ▸ | HRH1 | P35367 | 1/20 | 0.43 |
| ▸ | SCN1A | P35498 | 1/20 | 0.43 |
| ▸ | SCN4A | P35499 | 1/20 | 0.43 |
| ▸ | BLM | P54132 | 1/20 | 0.43 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.43 |
| ▸ | CACNA1D | Q01668 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | CACNA1S | Q13698 | 1/20 | 0.43 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.43 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.43 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.43 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9810970 | 0.92 | ITGA4 (0.73) | AKR1B1AKR1A1ITGA4CACNA1FALDH1A1 | |
| SCHEMBL25892565 | 0.91 | AKR1B1 (0.70) | AKR1B1AKR1A1ITGA4 | |
| SCHEMBL20845832 | 0.91 | AKR1A1 (1.00) | AKR1B1AKR1A1ITGA4 | |
| SCHEMBL9671558 | 0.82 | AKR1B1 (0.59) | AKR1B1AKR1A1ITGA4 | |
| Imirestat SCHEMBL49034 | 0.79 | AKR1A1 (1.00) | AKR1B1AKR1A1ITGA4 | |
| SCHEMBL9811003 | 0.79 | AKR1A1 (0.65) | AKR1B1AKR1A1ITGA4CACNA1FALDH1A1 | |
| Imirestat SCHEMBL30924520 | 0.79 | AKR1A1 (1.00) | AKR1B1AKR1A1ITGA4 | |
| SCHEMBL22380780 | 0.79 | AKR1B1 (0.65) | AKR1B1AKR1A1ITGA4CACNA1FALDH1A1 | |
| SCHEMBL11001789 | 0.79 | AKR1B1 (1.00) | AKR1B1AKR1A1ITGA4 | |
| SCHEMBL21095587 | 0.75 | AKR1A1 (0.59) | AKR1B1AKR1A1ITGA4CACNA1FALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230190710-A1 | COMPOSITIONS AND METHODS OF REDUCING SERUM CHOLESTEROL AND PCSK9 | UNIV CASE WESTERN RESERVE (US) | 2023-06-22 | — | — | US | disclosed |
| US-20220002552-A1 | SUBSTITUTED POLYFLUORENE COMPOUNDS | BioLegend, Inc. (US) | 2022-01-06 | — | — | US | disclosed |
| US-20220002552-A1 | SUBSTITUTED POLYFLUORENE COMPOUNDS | BioLegend, Inc. (US) | 2022-01-06 | — | — | US | disclosed |
| US-11155714-B2 | Substituted polyfluorene compounds | BioLegend, Inc. (US) | 2021-10-26 | — | — | US | disclosed |
| US-11155714-B2 | Substituted polyfluorene compounds | BioLegend, Inc. (US) | 2021-10-26 | — | — | US | disclosed |
| US-20190203052-A1 | SUBSTITUTED POLYFLUORENE COMPOUNDS | BIOLEGEND (US) | 2019-07-04 | — | — | US | disclosed |
| US-20190203052-A1 | SUBSTITUTED POLYFLUORENE COMPOUNDS | BIOLEGEND (US) | 2019-07-04 | — | — | US | disclosed |
| WO-2019060720-A1 | COMPOSITIONS AND METHODS OF REDUCING SERUM CHOLESTEROL AND PCSK9 | CASE WESTERN RESERVE UNIVERSITY (US) | 2019-03-28 | — | — | WO | disclosed |
| WO-2018009861-A1 | SUBSTITUTED POLYFLUORENE COMPOUNDS | BIOLEGEND (US) | 2018-01-11 | — | — | WO | disclosed |
| EP-0092385-B1 | HYDANTOIN DERIVATIVES FOR USE IN INHIBITING ALDOSE REDUCTASE ACTIVITY, COMPOSITIONS THEREFOR AND PROCESS FOR PREPARING SPIRO-FLUOREN COMPOUNDS | ALCON LABORATORIES, INC. (US) | 1991-06-12 | — | — | EP | disclosed |
| US-4540700-A | Treatment of diabetic complications with certain spiro-imidazolidine-diones | ALCON LABORATORIES, INC. (US) | 1985-09-10 | — | — | US | disclosed |
| US-4436745-A | TETRACYCLIC SPIROHYDANTOINS | ALCON LABORATORIES, INC. (US) | 1984-03-13 | — | — | US | disclosed |
| WO-1983003543-A1 | METHOD OF INHIBITING ALDOSE REDUCTASE ACTIVITY, COMPOSITIONS THEREFOR AND PROCESS FOR PREPARING SPIRO-FLUOROFLUOREN AND SPIRO-DIFLUOROFLUOREN COMPOUNDS | ALCON LAB INC (US) | 1983-10-27 | — | — | WO | disclosed |
| EP-0092385-A2 | Hydantoin derivatives for use in inhibiting aldose reductase activity, compositions therefor and process for preparing spiro-fluoren compounds | ALCON LABORATORIES, INC. (US) | 1983-10-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230190710-A1 | COMPOSITIONS AND METHODS OF REDUCING SERUM CHOLESTEROL AND PCSK9 | PCSK9, HMGCR, PCSK7 | AKR1B1 9/4885AKR1A1 8/4885ITGA4 4832/4885 |
| US-11155714-B2 | Substituted polyfluorene compounds | PARG, PFAS, PARN | AKR1B1 3073/4885AKR1A1 2953/4885ITGA4 2651/4885 |
| US-20220002552-A1 | SUBSTITUTED POLYFLUORENE COMPOUNDS | PARG, PFAS, PARN | AKR1B1 3073/4885AKR1A1 2953/4885ITGA4 2651/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.